JP2008520739A - 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法 - Google Patents

長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法 Download PDF

Info

Publication number
JP2008520739A
JP2008520739A JP2007543444A JP2007543444A JP2008520739A JP 2008520739 A JP2008520739 A JP 2008520739A JP 2007543444 A JP2007543444 A JP 2007543444A JP 2007543444 A JP2007543444 A JP 2007543444A JP 2008520739 A JP2008520739 A JP 2008520739A
Authority
JP
Japan
Prior art keywords
dpan
dihydroxy
oil
lcpufa
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520739A5 (https=
Inventor
リンダ メアリー アーテルバーン
ウィリアム バークレー
ビンディ ダンギ
ジェームズ フラット
ユング リー
エルスウィク メアリー ヴァン
Original Assignee
マーテック・バイオサイエンシーズ・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーテック・バイオサイエンシーズ・コーポレーション filed Critical マーテック・バイオサイエンシーズ・コーポレーション
Publication of JP2008520739A publication Critical patent/JP2008520739A/ja
Publication of JP2008520739A5 publication Critical patent/JP2008520739A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2007543444A 2004-11-19 2005-11-21 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法 Pending JP2008520739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62984204P 2004-11-19 2004-11-19
US72903805P 2005-10-21 2005-10-21
PCT/US2005/042462 WO2006055965A2 (en) 2004-11-19 2005-11-21 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2008520739A true JP2008520739A (ja) 2008-06-19
JP2008520739A5 JP2008520739A5 (https=) 2009-01-15

Family

ID=36407879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543444A Pending JP2008520739A (ja) 2004-11-19 2005-11-21 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法

Country Status (13)

Country Link
US (2) US7884131B2 (https=)
EP (1) EP1824809A4 (https=)
JP (1) JP2008520739A (https=)
KR (1) KR20070090928A (https=)
CN (1) CN101102988B (https=)
AU (1) AU2005306320B2 (https=)
BR (1) BRPI0516803A (https=)
CA (1) CA2588166A1 (https=)
EA (1) EA010802B1 (https=)
IL (1) IL183246A0 (https=)
MX (1) MX2007006049A (https=)
NZ (1) NZ555394A (https=)
WO (1) WO2006055965A2 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026106A1 (ja) * 2010-08-25 2012-03-01 国立大学法人 東京大学 光学活性な新規抗炎症性化合物及びその製造方法
JP2013500966A (ja) * 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
JP2015522535A (ja) * 2012-05-10 2015-08-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
JP2016505016A (ja) * 2013-01-11 2016-02-18 マサチューセッツ アイ アンド イヤー インファーマリー 炎症及び血管形成を減少させるｃｙｐ４５０脂質メタボライト
JP2016520612A (ja) * 2013-05-30 2016-07-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
JP2018506584A (ja) * 2015-02-09 2018-03-08 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US12006319B2 (en) 2018-05-25 2024-06-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US12213975B2 (en) 2018-08-31 2025-02-04 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
EP1983977A4 (en) * 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
JP2009545527A (ja) * 2006-07-19 2009-12-24 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 粘膜炎の治療用の組成物及び方法
EP2131833A2 (en) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
EP2120920A4 (en) * 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
PE20090186A1 (es) * 2007-03-23 2009-03-20 Novartis Ag Composicion farmaceutica que comprende una sal de cobre recubierta o encapsulada
US20100159540A1 (en) * 2007-03-26 2010-06-24 Ana Rodriguez Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
CA2699483A1 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
ES2792676T3 (es) 2008-09-16 2020-11-11 Brigham & Womens Hospital Inc Compuestos del ácido 14-hidroxi-docosahexaenoico
PT2349250T (pt) * 2008-10-31 2017-07-25 Lipid Pharmaceuticals Ehf Ácidos gordos para uso como um medicamento
EP2415748A4 (en) * 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
CA2756528A1 (en) * 2009-04-17 2010-10-21 Celavista Pharmaceuticals Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
CA2772618C (en) 2009-09-01 2018-08-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
WO2012170791A2 (en) * 2011-06-10 2012-12-13 The Brigham And Women's Hospital, Inc. Docosahexaenoyl ethanolamides
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US10322118B2 (en) * 2012-04-10 2019-06-18 Trustees Of Dartmouth College Compounds and methods for inhibiting Cif virulence factor
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
WO2014130894A1 (en) * 2013-02-21 2014-08-28 University Of Southern California Compositions for the treatment of inflammatory diseases
WO2014143272A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US20180208536A1 (en) * 2015-07-20 2018-07-26 The Brigham And Women's Hospital, Inc. Elucidation of Novel 13-Series Resolvins that Increase with Atorvastatin and Clear Infections
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
WO2019104315A1 (en) * 2017-11-27 2019-05-31 Brown University Compositions and methods using lipids for treating neurological disease
WO2019104311A1 (en) * 2017-11-27 2019-05-31 Brown University Compositions and methods for suppressing neurological disease
EP3792351A4 (en) 2018-04-16 2022-01-19 Korea Research Institute of Bioscience and Biotechnology Method for producing multi-hydroxy derivatives of polyunsaturated fatty acids
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
WO2024229108A1 (en) * 2023-05-01 2024-11-07 The Regents Of The University Of California In-situ production of anti-inflammatory lipids using milk fat globules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63238075A (ja) * 1987-03-24 1988-10-04 Mitsumaru Kagaku Kk 高度不飽和脂肪酸からのラクトン類の製造法
JPH05286956A (ja) * 1992-04-06 1993-11-02 Nippon Suisan Kaisha Ltd ドコサペンタエン酸モノエポキシ体、及びその製造法
JPH11209259A (ja) * 1998-01-20 1999-08-03 Noevir Co Ltd 皮膚化粧料
WO2002092540A1 (en) * 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
JP2003525880A (ja) * 2000-02-16 2003-09-02 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
CZ281096B6 (cs) * 1994-06-30 1996-06-12 Jindřich Mudr. Drsc. Mourek Tuková složka mléčné výživy a dětská výživa
US5955496A (en) 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
ATE236627T1 (de) 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19757414A1 (de) 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
KR100423013B1 (ko) 1999-03-04 2004-03-12 산토리 가부시키가이샤 도코사펜타엔산 함유물질의 이용
CA2378968A1 (en) 1999-07-07 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Process for producing hydroxylated fatty acid and o-lactones
EP1228026B1 (en) 1999-11-09 2004-01-02 Alcon Inc. 15-hydroxyeicosatetraenoic acid-related compounds and methods of use
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US7154022B2 (en) 2000-10-06 2006-12-26 Board Of Trustees Operating Michigan State University Divinyl ether synthase gene, and protein and uses thereof
AU2002365167A1 (en) * 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
WO2003084305A2 (en) 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
FR2843124B1 (fr) 2002-08-02 2004-10-15 Goemar Lab Sa Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US20040166130A1 (en) 2002-12-23 2004-08-26 L'oreal Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63238075A (ja) * 1987-03-24 1988-10-04 Mitsumaru Kagaku Kk 高度不飽和脂肪酸からのラクトン類の製造法
JPH05286956A (ja) * 1992-04-06 1993-11-02 Nippon Suisan Kaisha Ltd ドコサペンタエン酸モノエポキシ体、及びその製造法
JPH11209259A (ja) * 1998-01-20 1999-08-03 Noevir Co Ltd 皮膚化粧料
JP2003525880A (ja) * 2000-02-16 2003-09-02 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
WO2002092540A1 (en) * 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
JP2004536059A (ja) * 2001-05-14 2004-12-02 マーテック バイオサイエンシズ ボールダー コーポレーション 微生物、遺伝的に改変された植物種子および海洋生物由来のω−３および／またはω−６高度不飽和脂肪酸を含有する極性脂質の豊富な画分の生成および使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6011060206; ＭＩＬＫＳ，Ｍ．Ｍ．　ａｎｄ　ＳＰＲＥＣＨＥＲ，Ｈ．: 'Ｍｅｔａｂｏｌｉｓｍ　ｏｆ　４，７，１０，１３，１６-ｄｏｃｏｓａｐｅｎｔａｅｎｏｉｃ　ａｃｉｄ　ｂｙ　ｈｕｍａｎ　ｐｌａｔｅｌｅｔ　ｃｙｃｌｏｏｘｙｇｅｎａｓｅ　ａｎｄ　ｌｉｐｏｘｙｇｅｎａｓｅ' Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ，　Ｌｉｐｉｄｓ　ａｎｄ　Ｌｉｐｉｄ　Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌ．８３５，　Ｎｏ．１, 1985, ｐ．２９-３５ *
JPN6011060209; ＳＰＲＥＣＨＥＲ，Ｈ．　ａｎｄ　ＣＡＲＥＡＧＡ，Ｍ．Ｍ．: 'Ｍｅｔａｂｏｌｉｓｍ　ｏｆ　（ｎ-６）　ａｎｄ　（ｎ-３）　ｐｏｌｙｕｎｓａｔｕｒａｔｅｄ　ｆａｔｔｙ　ａｃｉｄｓ　ｂｙ　ｈｕｍａｎ　ｐｌａｔｅｌｅｔｓ' Ｐｒｏｓｔａｇｌａｎｄｉｎｓ，　Ｌｅｕｋｏｔｒｉｅｎｅｓ　ａｎｄ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．２３，　Ｎｏ．２-３, 1986, ｐ．１２９-１３４ *
JPN6011060211; ＯＬＩＷ，Ｅ．Ｈ．　ａｎｄ　ＳＰＲＥＣＨＥＲ，Ｈ．: 'Ｍｅｔａｂｏｌｉｓｍ　ｏｆ　ｐｏｌｙｕｎｓａｔｕｒａｔｅｄ　ｆａｔｔｙ　ａｃｉｄｓ　ｂｙ　ａｎ　（ｎ-６）-ｌｉｐｏｘｙｇｅｎａｓｅ　ａｓｓｏｃｉａｔｅｄ　ｗｉｔｈ　ｈｕｍａｎ　ｅｊａｃｕｌａｔｅｓ' Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ，　Ｌｉｐｉｄｓ　ａｎｄ　Ｌｉｐｉｄ　Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌ．１００２，　Ｎｏ．３, 1989, ｐ．２８３-２９１ *
JPN6011060212; ＧＵＥＲＲＩＥＲＯ，Ａ．　ｅｔ　ａｌ．: 'Ｈｙｄｒｏｘｙｅｉｃｏｓａｔｅｔｒａｅｎｏｉｃ，　ｈｙｄｒｏｘｙｅｉｃｏｓａｐｅｎｔａｅｎｏｉｃ，　ｈｙｄｒｏｘｙｄｏｃｏｓａｐｅｎｔａｅｎｏｉｃ，　ａｎｄ　ｈｙｄｒｏｘｙｄｏｃｏｓａｈｅｘａｅｎｏｉ' Ｊｏｕｒｎａｌ　ｏｆ　Ｎａｔｕｒａｌ　Ｐｒｏｄｕｃｔｓ Ｖｏｌ．５３，　Ｎｏ．１, 1990, ｐ．５７-６１ *
JPN6011060213; ＫＡＲＡＮＩＡＮ，Ｊ．Ｗ．　ｅｔ　ａｌ．: 'Ｉｎｈｉｂｉｔｏｒｙ　ｅｆｆｅｃｔｓ　ｏｆ　ｎ-６　ａｎｄ　ｎ-３　ｈｙｄｒｏｘｙ　ｆａｔｔｙ　ａｃｉｄｓ　ｏｎ　ｔｈｒｏｍｂｏｘａｎｅ　（Ｕ４６６１９）-ｉｎｄｕｃｅｄ　ｓｍｏｏｔｈ　ｍｕｓｃｌｅ' Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｔｈｅｒａｐｅｕｔｉｃｓ Ｖｏｌ．２７０，　Ｎｏ．３, 1994, ｐ．１１０５-１１０９ *
JPN6011060215; ＨＡＶＩＶ，Ｆ．　ｅｔ　ａｌ．: 'Ｓｔｒｕｃｔｕｒａｌ　ｒｅｑｕｉｒｅｍｅｎｔｓ　ｆｏｒ　ｔｈｅ　ｉｎｈｉｂｉｔｉｏｎ　ｏｆ　５-ｌｉｐｏｘｙｇｅｎａｓｅ　ｂｙ　１５-ｈｙｄｒｏｘｙｅｉｃｏｓａ-５，８，１１，１３-ｔｅｔｒａｅｎｏｉ' Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３０，　Ｎｏ．２, 1987, ｐ．２５４-２６３ *
JPN6011060216; ＭＡＮＣＩＮＩ，Ｉ．　ｅｔ　ａｌ．: 'Ｎｏｖｅｌ　１０-ｈｙｄｒｏｘｙｄｏｃｏｓａｐｏｌｙｅｎｏｉｃ　ａｃｉｄｓ　ｆｒｏｍ　ｄｅｅｐ-ｗａｔｅｒ　ｓｃｌｅｒａｃｔｉｎｉａｎ　ｃｏｒａｌｓ' Ｈｅｌｖｅｔｉｃａ　Ｃｈｉｍｉｃａ　Ａｃｔａ Ｖｏｌ．８２，　Ｎｏ．５, 1999, ｐ．６７７-６８４ *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017114897A (ja) * 2009-07-31 2017-06-29 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
JP2013500966A (ja) * 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
JPWO2012026106A1 (ja) * 2010-08-25 2013-10-28 国立大学法人 東京大学 光学活性な新規抗炎症性化合物及びその製造方法
WO2012026106A1 (ja) * 2010-08-25 2012-03-01 国立大学法人 東京大学 光学活性な新規抗炎症性化合物及びその製造方法
JP2015522535A (ja) * 2012-05-10 2015-08-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
JP2018193378A (ja) * 2012-05-10 2018-12-06 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
JP2016505016A (ja) * 2013-01-11 2016-02-18 マサチューセッツ アイ アンド イヤー インファーマリー 炎症及び血管形成を減少させるｃｙｐ４５０脂質メタボライト
JP2016520612A (ja) * 2013-05-30 2016-07-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
JP2019163265A (ja) * 2013-05-30 2019-09-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 新規ｎ−３イムノリソルベント：構造及び作用
US11667598B2 (en) 2013-05-30 2023-06-06 The Brigham & Women's Hospital Inc. N-3 immunoresolvents: structures and actions
JP2018506584A (ja) * 2015-02-09 2018-03-08 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
JP7025212B2 (ja) 2015-02-09 2022-02-24 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
US11608342B2 (en) 2015-07-07 2023-03-21 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
US12006319B2 (en) 2018-05-25 2024-06-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US12466832B2 (en) 2018-05-25 2025-11-11 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
US12213975B2 (en) 2018-08-31 2025-02-04 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease

Also Published As

Publication number Publication date
IL183246A0 (en) 2007-08-19
US20060241088A1 (en) 2006-10-26
US20110178047A1 (en) 2011-07-21
MX2007006049A (es) 2007-07-24
KR20070090928A (ko) 2007-09-06
EP1824809A2 (en) 2007-08-29
EA200701100A1 (ru) 2007-10-26
US7884131B2 (en) 2011-02-08
EP1824809A4 (en) 2010-03-03
AU2005306320A1 (en) 2006-05-26
WO2006055965A2 (en) 2006-05-26
WO2006055965A3 (en) 2006-11-30
CN101102988B (zh) 2011-12-14
EA010802B1 (ru) 2008-12-30
BRPI0516803A (pt) 2008-09-23
AU2005306320B2 (en) 2011-09-08
CA2588166A1 (en) 2006-05-26
CN101102988A (zh) 2008-01-09
NZ555394A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
JP2008520739A (ja) 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
JP2010519311A (ja) 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
US7893106B2 (en) Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
DE60124256T3 (de) Aspirin-ausgelöste lipidmediatoren
US20090320148A1 (en) Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
AU2014358123B2 (en) Dihomo-gamma-linolenic acid-containing microbial oil and dihomo-gamma-linolenic acid-containing microbial biomass
JP2010519311A5 (https=)
JP7242769B2 (ja) 遊離多価不飽和脂肪酸含有組成物及びその製造方法
AU2011253846A1 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20110027841A1 (en) Method for preparation of oxylipins
HK1105948B (en) Aspirin triggered lipid mediators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121017